BeOne Medicines insider sells $0.35 M in ADS for RSU tax withholding

Q: Why did ONC鈥檚 President & COO sell shares on June 23 2025?

The 1,363 ADS sale was solely to cover tax withholding triggered by RSU vesting, as noted in the Form 4 footnote.

Q: How many BeOne Medicines shares does Wu Xiaobin own after the transaction?

He now holds 1,228,328 ordinary shares and 16,365 ADSs , including 4,000 ADS held indirectly via spouse.

Q: Is the June 2025 insider sale considered material for ONC investors?

No. The disposal equals roughly 1.2 % of Wu鈥檚 total holdings and is valued at about $0.35 million , below materiality thresholds.

[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BeOne Medicines (ONC) filed a routine Form 4 reporting a small insider transaction by President & COO Wu Xiaobin.

On 06/23/2025, Wu disposed of 1,363 American Depositary Shares at $260 per ADS (鈮�$0.35 million) to satisfy mandatory tax-withholding on vested RSUs. Post-sale holdings remain substantial at 1,228,328 ordinary shares plus 16,365 ADSs (4,000 held indirectly by spouse). No other changes to ownership, compensation, or governance were disclosed.

06/25/2025 - 05:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wu Xiaobin

(Last)

(First)

(Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL

4051

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares								1,228,328	D
American Depositary Shares⁽¹⁾								12,365	D
American Depositary Shares⁽¹⁾								4,000	I	By Wife
American Depositary Shares⁽¹⁾	06/23/2025		S⁽²⁾		1,363	D	$260	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Why did ONC鈥檚 President & COO sell shares on June 23 2025?

The 1,363 ADS sale was solely to cover tax withholding triggered by RSU vesting, as noted in the Form 4 footnote.

How many BeOne Medicines shares does Wu Xiaobin own after the transaction?

He now holds 1,228,328 ordinary shares and 16,365 ADSs, including 4,000 ADS held indirectly via spouse.

Is the June 2025 insider sale considered material for ONC investors?

No. The disposal equals roughly 1.2 % of Wu鈥檚 total holdings and is valued at about $0.35 million, below materiality thresholds.

Did the Form 4 reveal any new governance or compensation changes at ONC?

No. The filing only details the routine tax-related share sale; no governance or compensation changes were reported.

AG真人官方

[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

FAQ

Why did ONC鈥檚 President & COO sell shares on June 23 2025?

How many BeOne Medicines shares does Wu Xiaobin own after the transaction?

Is the June 2025 insider sale considered material for ONC investors?

Did the Form 4 reveal any new governance or compensation changes at ONC?

NASDAQ:ONC

ONC Rankings

ONC Latest News

ONC Latest SEC Filings

ONC Stock Data

AG真人官方

Trending News

[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

FAQ

Why did ONC鈥檚 President & COO sell shares on June 23 2025?

How many BeOne Medicines shares does Wu Xiaobin own after the transaction?

Is the June 2025 insider sale considered material for ONC investors?

Did the Form 4 reveal any new governance or compensation changes at ONC?

NASDAQ:ONC

ONC Rankings

ONC Latest News

ONC Latest SEC Filings

ONC Stock Data